Amplify Weight Loss Drug & Treatment ETF (THNR) Dividend History

Company News

• Can Eli Lilly ETFs Surge on Approval of Alzheimer's Drug?

  On Jun 10, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted 11-0, unanimously recommending the approval of Eli Lilly's (LLY) Alzheimer's disease drug, donanemab.

  Zacks Investment Research

  Featured Companies: BIIB IHE LLY MEDX PRTA SAVA
• ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential

  With more than 10% of the global population now suffering from obesity, the share prices of companies providing the latest weight-loss drugs have surged. However, according to industry observers, investors considering exposure through the newly launched weight-loss exchange-traded funds (ETFs) need to evaluate their potential. The Roundhill GLP-1 Weight Loss ETF (NASDAQ:OZEM) and the Amplify Weight Loss Drug and Treatment ETF (NYSE:THNR) debuted on May 21 with an expense ratio of 0.59%. Both ETFs have significant weightings in industry giants Eli Lilly And Co (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO), with OZEM and THNR allocating about 40% and 30%, respectively, to these companies. Eli Lilly and ...Full story available on Benzinga.com

  Benzinga

  Featured Companies: LLY OZEM
• ETFs to Profit from the Weight Loss Drug Boom

  The market for GLP-1 drugs could soar to $130 billion by 2030

  Zacks Investment Research

  Featured Companies: HRTS LLY NVDA OZEM TSLA